PriceTargets.com logo

Daxor - DXR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.75
  • Forecasted Upside: 174.69%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.01 As of 11/15/2024 01:00 AM ET
▲ +0.19 (2.15%)

This chart shows the closing price for DXR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Daxor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXR

Analyst Price Target is $24.75
▲ +174.69% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Daxor in the last 3 months. The average price target is $24.75, with a high forecast of $24.75 and a low forecast of $24.75. The average price target represents a 174.69% upside from the last price of $9.01.

This chart shows the closing price for DXR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Daxor.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/9/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$24.50 ➝ $24.75
(Data available from 11/17/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Daxor logo
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
Read More

Today's Range

Now: $9.01
Low: $8.73
High: $9.03

50 Day Range

MA: $9.05
Low: $8.60
High: $9.79

52 Week Range

Now: $9.01
Low: $7.11
High: $10.04

Volume

2,386 shs

Average Volume

7,457 shs

Market Capitalization

$43.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Daxor?

The following sell-side analysts have issued reports on Daxor in the last year: Ascendiant Capital Markets.
View the latest analyst ratings for DXR.

What is the current price target for Daxor?

0 Wall Street analysts have set twelve-month price targets for Daxor in the last year. Their average twelve-month price target is $24.75, suggesting a possible upside of 174.7%. Ascendiant Capital Markets has the highest price target set, predicting DXR will reach $24.75 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $24.75 for Daxor in the next year.
View the latest price targets for DXR.

What is the current consensus analyst rating for Daxor?

Daxor currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DXR will outperform the market and that investors should add to their positions of Daxor.
View the latest ratings for DXR.

What other companies compete with Daxor?

Other companies that are similar to Daxor include BrainsWay, InfuSystem, Alpha Tau Medical, Health Sciences Acquisitions Co. 2 and Inovio Pharmaceuticals. Learn More about companies similar to Daxor.

How do I contact Daxor's investor relations team?

Daxor's physical mailing address is 109 Meco Lane, Oak Ridge, TN 37830, United States, . The company's listed phone number is 212-244-0555 and its investor relations email address is [email protected]. The official website for Daxor is www.daxor.com. Learn More about contacing Daxor investor relations.